Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/7/2018
SIETES contiene 92427 citas

 
 
 1 a 20 de 698 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Tsujimoto T, Kajio H, Shapiro MF, Sugiyama T. Risk of all-cause mortality in diabetic patients taking ß-blockers. Mayo Clin Proc 2017;93:409-18. [Ref.ID 102505]
2. Cita con resumen
3. Cita con resumen
Finch A, Kubler P. The management of gout. Australian Prescriber 2016;39:1 de agosto. [Ref.ID 100572]
4.Enlace a cita original Cita con resumen
Anónimo. Metformin-containing drugs: drug safety communication - Revised warnings for certain patients with reduced kidney function. FDA U.S. Food and Drug Administration 2016:8 de abril. [Ref.ID 100111]
5. Cita con resumen
Boussageon R, Gueyffier F, Cornu C. Metformin as firstline treatment for type 2 diabetes: are we sure?. BMJ 2016;352:h6748. [Ref.ID 99967]
6. Cita con resumen
Anónimo. Thalidomide: reduced starting dose in patients older than age 75 years. Drug Safety Update 2015;9:2. [Ref.ID 99746]
7. Cita con resumen
Sennesael AL, Dogné J-M, Spinewine A. Optimizing the safe use of direct oral anticoagulants in older patients. A teachable moment. JAMA Intern Med 2015;175:1608-9. [Ref.ID 99648]
8. Cita con resumen
Stam-Slob MC, Lambalk CB, van de Ree MA. Contraceptive and hormonal treatment options for women with history of venous thromboembolism. BMJ 2015;351:h4847. [Ref.ID 99595]
9. Cita con resumen
Hung SC , Chang YK, Liu JS, Kuo KL, Chen YH, Hsu CC, Tarng DC. Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study. The Lancet Diabetes Endocrinology 2015;3:605-14. [Ref.ID 99247]
10. Cita con resumen
Hung S-C, Chang Y-K, Liu J-S, Kuo KL, Chen YH, Hsu CC, Tarng DC. Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study. The Lancet Diabetes & Endocrinology 2015;3:605-14. [Ref.ID 99203]
11. Cita con resumen
Anónimo. FDA approves anti-clotting drug Savaysa. FDA U.S. Food and Drug Administration 2015:8 de enero. [Ref.ID 98703]
12. Cita con resumen
Hernández I, Baik SH, Piñera A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med 2014;175:18-24. [Ref.ID 98701]
14. Cita con resumen
Anónimo. FDA approves combo treatment for Alzheimer’s-related dementia. DIA Daily 2014:29 de diciembre. [Ref.ID 98396]
17. Cita con resumen
Liu G, Yan Y-P, Zheng X-X, Xu Y-L, Lu J, Hui R-T, Huang X-H. Meta-analysis of nonsteroidal anti-inflammatory drug use and risk of atrial fibrillation. Am J Cardiol 2014;114:1523-9. [Ref.ID 97244]
18. Cita con resumen
Wright DFB, Al-Sallami HS, Duffull SB. Is the dose of dabigatran really more predictable than warfarin?. Br J Clin Pharmacol 2013;76:997-8. [Ref.ID 96634]
19. Cita con resumen
Bastiansen A, Eggert S, Pedersen E. Pharmacokinetics of terbutaline in chronic kidney disease. Eur J Clin Pharmacol 2013;69:1951-4. [Ref.ID 96502]
20. Cita con resumen
McCallum PK, Mathur R, Hull SA, Saja K, Green L, Morris JK, Ashman N. Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: a cross-sectional study. BMJ Open 2013;3:e003343. [Ref.ID 96277]
Seleccionar todas
 
 1 a 20 de 698 siguiente >>